ISSN - | E-ISSN -2822-2288
Hepatitis B Virus Reactivation in a Case With Non Hodgkin Lymphoma Treated by Rituximab Containing Regimen: Treatment With Dual Anti-Viral Combination [EJMA]
EJMA. 2022; 2(3): 142-145 | DOI: 10.14744/ejma.2022.83997

Hepatitis B Virus Reactivation in a Case With Non Hodgkin Lymphoma Treated by Rituximab Containing Regimen: Treatment With Dual Anti-Viral Combination

Reyhan Sevil Soysal1, Semra Paydas2
1Department of Internal Medicine, Cukurova University Faculty of Medicine, Adana, Türkiye
2Department of Medical Oncology, Cukurova University Faculty of Medicine, Adana, Türkiye

Rituximab is a chimeric monoclonal antibody targeting CD20 expressed on pre-B and mature B lymphocytes. This antibody has been used for a more than 20 years in cases with B cell non-Hodgkin lymphomas (B-NHL). The use of rituximab has some complications and one of the most important complications is Hepatitis B reactivation (HBV-R). HBV-R can lead to severe complications like hepatitis reactivation and death. Here we present a case with B-NHL developing HBV reactivation and successful treatment with combined anti-viral treatment.

Keywords: Hbv reactivation, rituximab, non-Hodgkin lymphoma

Reyhan Sevil Soysal, Semra Paydas. Hepatitis B Virus Reactivation in a Case With Non Hodgkin Lymphoma Treated by Rituximab Containing Regimen: Treatment With Dual Anti-Viral Combination. EJMA. 2022; 2(3): 142-145

Corresponding Author: Reyhan Sevil Soysal, Türkiye
Manuscript Language: English